Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

Arthur Vandenbark, Jianya Huan, Marisa Agotsch, Dorian La Tocha, Susan Goelz, Halina Offner, Stefan Lanker, Dennis Bourdette

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Disease modifying effects of interferon (IFN)-β therapy in patients with multiple sclerosis (MS) may be mediated in part through enhanced immunoregulation by the CD56bright subpopulation of natural killer (NK) cells and by Foxp3+ (not italicized) CD4+CD25+ regulatory T cells (Treg). We found that IFN-β-1a(IM) treatment of relapsing-remitting (RR)MS subjects over 12 months significantly increased both percentage of CD56bright NK cells and Foxp3 mRNA expression compared to baseline values, untreated RRMS subjects and healthy controls (HC). This striking enhancement of two prominent immunoregulatory pathways lends support to the idea that beneficial effects of IFN-β-1a in MS include control of pernicious autoimmunity.

Original languageEnglish (US)
Pages (from-to)125-128
Number of pages4
JournalJournal of Neuroimmunology
Volume215
Issue number1-2
DOIs
StatePublished - Oct 30 2009

Fingerprint

Natural Killer Cells
Interferons
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Regulatory T-Lymphocytes
Autoimmunity
Healthy Volunteers
Therapeutics
Messenger RNA
Interferon beta-1a

Keywords

  • CD56 NK cells
  • Foxp3 expression
  • IFN-β-1a
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. / Vandenbark, Arthur; Huan, Jianya; Agotsch, Marisa; La Tocha, Dorian; Goelz, Susan; Offner, Halina; Lanker, Stefan; Bourdette, Dennis.

In: Journal of Neuroimmunology, Vol. 215, No. 1-2, 30.10.2009, p. 125-128.

Research output: Contribution to journalArticle

@article{c73eb4fbb7a444028dd60b0780ba3214,
title = "Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis",
abstract = "Disease modifying effects of interferon (IFN)-β therapy in patients with multiple sclerosis (MS) may be mediated in part through enhanced immunoregulation by the CD56bright subpopulation of natural killer (NK) cells and by Foxp3+ (not italicized) CD4+CD25+ regulatory T cells (Treg). We found that IFN-β-1a(IM) treatment of relapsing-remitting (RR)MS subjects over 12 months significantly increased both percentage of CD56bright NK cells and Foxp3 mRNA expression compared to baseline values, untreated RRMS subjects and healthy controls (HC). This striking enhancement of two prominent immunoregulatory pathways lends support to the idea that beneficial effects of IFN-β-1a in MS include control of pernicious autoimmunity.",
keywords = "CD56 NK cells, Foxp3 expression, IFN-β-1a, Multiple sclerosis",
author = "Arthur Vandenbark and Jianya Huan and Marisa Agotsch and {La Tocha}, Dorian and Susan Goelz and Halina Offner and Stefan Lanker and Dennis Bourdette",
year = "2009",
month = "10",
day = "30",
doi = "10.1016/j.jneuroim.2009.08.007",
language = "English (US)",
volume = "215",
pages = "125--128",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

AU - Vandenbark, Arthur

AU - Huan, Jianya

AU - Agotsch, Marisa

AU - La Tocha, Dorian

AU - Goelz, Susan

AU - Offner, Halina

AU - Lanker, Stefan

AU - Bourdette, Dennis

PY - 2009/10/30

Y1 - 2009/10/30

N2 - Disease modifying effects of interferon (IFN)-β therapy in patients with multiple sclerosis (MS) may be mediated in part through enhanced immunoregulation by the CD56bright subpopulation of natural killer (NK) cells and by Foxp3+ (not italicized) CD4+CD25+ regulatory T cells (Treg). We found that IFN-β-1a(IM) treatment of relapsing-remitting (RR)MS subjects over 12 months significantly increased both percentage of CD56bright NK cells and Foxp3 mRNA expression compared to baseline values, untreated RRMS subjects and healthy controls (HC). This striking enhancement of two prominent immunoregulatory pathways lends support to the idea that beneficial effects of IFN-β-1a in MS include control of pernicious autoimmunity.

AB - Disease modifying effects of interferon (IFN)-β therapy in patients with multiple sclerosis (MS) may be mediated in part through enhanced immunoregulation by the CD56bright subpopulation of natural killer (NK) cells and by Foxp3+ (not italicized) CD4+CD25+ regulatory T cells (Treg). We found that IFN-β-1a(IM) treatment of relapsing-remitting (RR)MS subjects over 12 months significantly increased both percentage of CD56bright NK cells and Foxp3 mRNA expression compared to baseline values, untreated RRMS subjects and healthy controls (HC). This striking enhancement of two prominent immunoregulatory pathways lends support to the idea that beneficial effects of IFN-β-1a in MS include control of pernicious autoimmunity.

KW - CD56 NK cells

KW - Foxp3 expression

KW - IFN-β-1a

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=70349741303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349741303&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2009.08.007

DO - 10.1016/j.jneuroim.2009.08.007

M3 - Article

C2 - 19758707

AN - SCOPUS:70349741303

VL - 215

SP - 125

EP - 128

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -